Sana Biotech is Doing an Exciting Preclinical Science Trial

Sana Biotechnology (SANA) is another high-valued cell treatment company that has yet to release any trial data. Despite this, it has a market capitalization of $1.4 billion. So, let’s have a look at what it’s all about. is essentially a subsidiary of Juno Therapeutics. Dr. Steve Harr, the company’s founder and CEO, was previously the CFO of Juno. Juno’s President of Research and Development was Sunil Agarwal, MD, Executive Vice President, Head of Development, and Chief Medical Officer. Juno has at least 5 individuals on the executive team.

Hans Bishop, Sana Chairman, is a Juno alum; in fact, he created Juno in 2013 and served as its President and Chief Executive Officer until Celgene bought it for $9 billion. Also worth noting is that throughout pre-IPO time, Arch Venture Partners, Juno’s principal investor, held a 28 percent ownership in the company. They currently possess more than a quarter of. According to the information I have, Arch Ventures started a new job in Sana at the end of last year. For the serious researcher, here’s a link to the 13G.

So this is simply a few of the same people hoping to repeat their Juno success. This is also the main reason why, despite the lack of clinical data, Sana is generating so much interest in the market. They have a fantastic scientific and research team. Goldman will join Sana star-studded team, which includes industry legends including Harvard geneticist Richard Mulligan (now executive vice chairman).

There’s also Terry Fry, the head of T cell therapeutics, who previously led the NIH’s paediatric oncology branch’s hematologic malignancies section; Ed Rebar, the chief technical officer from Sangamo Therapeutics; and Chuck Murry, the cell therapy CSO, who co-founded the Institute for Stem Cell and Regenerative Medicine in 2008.